Variant · Expression
HDAC2 Overexpression
CI-VAR-00003215Explore in graph →CIViC 3279
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28560068
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Breast Neoplasm1 | ||||||||
| HDAC2 Overexpression | Mocetinostat | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID9130To determine possible druggable gene targets, 18 histone deacetylases (HDACs) expression levels were evaluated from a cohort with 960 breast cancer samples and found that six of the HDACs (HDAC1, HDAC… (full text at CIViC) PMID 28560068 · Shan et al., 2017 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.